Monograph Details
|
|
Musculoskeletal Disorders
> Arthritis/rheumatic disorders
|
|
IMURAN |
| Manufacturer |
|
Prometheus Labs, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Immunosuppressant. |
| Generic Name |
|
Azathioprine 50mg; scored tabs. |
| Indications |
|
Severe, active, erosive rheumatoid arthritis unresponsive to rest, NSAIDs or gold. |
| Children |
|
Not recommended. |
| Adults |
|
1mg/kg per day in 1–2 divided doses. After 6–8 weeks, if needed, increase by 0.5mg/kg per day increments every 4 weeks; max 2.5mg/kg per day. Maintenance: use lowest effective dose. |
| Contraindications |
|
Pregnancy (Cat.D). |
| Precautions |
|
Be fully familiar with this product's toxicity before use. Impaired renal function. Monitor blood. Discontinue if ineffective after 12 weeks. Nursing mothers: not recommended. |
| Interactions |
|
Avoid concomitant gold, antimalarials or penicillamine. Reduce dose to ⅓ or ¼ with allopurinol. Prior treatment with alkylating agents increases cancer risk. Anemia, leukopenia with ACE inhibitors. May antagonize warfarin. |
| Adverse Reactions |
|
Severe leukopenia and/or thrombocytopenia, secondary infections, mutagenic and carcinogenic potential, nausea, pancreatitis, hepatotoxicity, rash, alopecia. |
| How Supplied |
|
Tabs—100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
